Board of Directors
Bruno Angelici, Member of the board
Bruno Angelici was executive vice president of AstraZeneca, with P&L responsibility for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa from 2001 until 2009. In 1998 Mr Angelici was appointed president of Zeneca, Japan, and was responsible for the successful merger of Astra and Zeneca in Japan. Previously, from 1989 Mr Angelici was president of Zeneca, France, having joined from Baxter International, where he held various management positions from 1978 to 1989.
Mr Angelici is a member of the Board of Directors of Smiths Group plc, UK, and a member of the Supervisory Board of Wolters Kluwer, NL. Further, he is member of the Global Advisory Board at Takeda Pharmaceutical Company Limited, Japan.
Mr Angelici has a BA in Business Administration from Ecole Superieure de Commerce Reims from 1971 and a degree in Law from Reims University from 1973, both in France. In addition, he has an MBA from Kellogg School of Management at NorthWestern University from 1978 and an AMP from Harvard Business School from 1993, both in the US.
Mr Angelici was first elected to the Board of Novo Nordisk A/S in March 2011 and has most recently been re-elected in March 2013. His term as a board member expires in March 2014.
In March 2013, the Board of Directors of Novo Nordisk A/S assessed that Mr Angelici is regarded as an independent board member as defined in Section 5.4.1 of the Recommendations on Corporate Governance designated by NASDAQ OMX Copenhagen (2011).
Mr Angelici became member of the Nomination Committee at Novo Nordisk A/S in April 2013.
In January 2013, the Board of Directors assessed that the special competences possessed by Mr Angelici that are important for the performance of his duties is his extensive global experience with two companies in the fields of pharmaceuticals and medical devices. Mr Angelici has in-depth knowledge of strategy, sales, marketing and governance of major companies.
Mr Angelici is a male French national, born April 1947.